Levine M M, McEwen J, Losonsky G, Reymann M, Harari I, Brown J E, Taylor D N, Donohue-Rolfe A, Cohen D, Bennish M
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
J Clin Microbiol. 1992 Jul;30(7):1636-41. doi: 10.1128/jcm.30.7.1636-1641.1992.
Acute- and convalescent-phase sera from 18 Thai patients and convalescent-phase sera from two Israeli patients and one Bangladeshi patient with Shigella dysenteriae 1 (Shiga) dysentery were tested by enzyme-linked immunosorbent assay to detect antibodies that bind S. dysenteriae lipopolysaccharide (LPS), Shiga holotoxin, or two synthetic peptides representing epitopes from the B subunit of Shiga toxin. Paired sera from 24 Maryland adults with Shigella flexneri 2a or Shigella sonnei diarrhea served as negative controls. Of the 16 paired Thai serum samples tested for immunoglobulin G LPS antibody, 10 had greater than or equal to 4-fold rises (the two subjects with the highest convalescent-phase titers exhibited toxin-neutralizing activity); acute-phase specimens from four of the remaining six individuals already had elevated Shiga LPS titers in their acute specimens ranging from 1:800 to 1:12,800. Similarly, convalescent-phase sera from the two Israeli patients and the Bangladeshi patient revealed LPS titers of 1:800 to 1:3,200. In contrast, none of the Maryland volunteers with S. flexneri or S. sonnei diarrhea manifested rises in Shiga anti-LPS (P less than 0.00001 versus 10 of 16 Thai patients). Only 4 of the 18 Thai patients had significant rise in antibody to purified Shiga toxin, while one of the two Israeli patients and the one Bangladeshi patient had elevated convalescent-phase titers. None of the sera that reacted with Shiga holotoxin had antibody that bound to the peptides. This report, which describes a search for serum antibodies that bind Shiga toxin in patients with Shiga dysentery, demonstrates such antibodies in only a minority of patients with bacteriologically confirmed disease. During Shiga dysentery, Shiga toxin may be elaborated in such small quantities in vivo that it fails to elicit an immune response in most patients even though it may exert biological effects. In this behavior Shiga toxin resembles tetanus toxin, another potent exotoxin that fails to elicit antitoxic responses in people who recover from clinical tetanus.
采用酶联免疫吸附测定法检测了18例泰国志贺氏痢疾杆菌1型(志贺氏)痢疾患者的急性期和恢复期血清,以及2例以色列患者和1例孟加拉国志贺氏痢疾杆菌1型痢疾患者的恢复期血清,以检测能与痢疾志贺氏菌脂多糖(LPS)、志贺氏全毒素或代表志贺氏毒素B亚基表位的两种合成肽结合的抗体。24例马里兰州患弗氏志贺氏菌2a或宋内氏志贺氏菌腹泻的成年人的配对血清用作阴性对照。在检测免疫球蛋白G LPS抗体的16份泰国配对血清样本中,10份有大于或等于4倍的升高(恢复期滴度最高的两名受试者表现出毒素中和活性);其余6人中,有4人的急性期样本中志贺氏LPS滴度已升高,范围为1:800至1:12,800。同样,两名以色列患者和孟加拉国患者的恢复期血清显示LPS滴度为1:800至1:3,200。相比之下,马里兰州患弗氏志贺氏菌或宋内氏志贺氏菌腹泻的志愿者中,无一例志贺氏抗LPS升高(与16例泰国患者中的10例相比,P<0.00001)。18例泰国患者中只有4例针对纯化志贺氏毒素的抗体有显著升高,而两名以色列患者中的1例和孟加拉国患者恢复期滴度升高。与志贺氏全毒素反应的血清中,无一例有与肽结合的抗体。本报告描述了在志贺氏痢疾患者中寻找能与志贺氏毒素结合的血清抗体的研究,结果显示在细菌学确诊的疾病患者中只有少数患者有此类抗体。在志贺氏痢疾期间,志贺氏毒素在体内的产生量可能极少,以至于即使它可能发挥生物学效应,也无法在大多数患者中引发免疫反应。志贺氏毒素的这种表现类似于破伤风毒素,另一种强效外毒素,在从临床破伤风康复的患者中也无法引发抗毒素反应。